✦ LIBER ✦

Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study

✍ Scribed by M. Wolzt; V. Fabrizii; G. T. Dorner; G. Zanaschka; P. Leufkens; W. J. J. Krauwinkel; H.-G. Eichler

Publisher: Springer
Year: 1998
Tongue: English
Weight: 320 KB
Volume: 54
Category: Article
ISSN: 0031-6970
DOI: 10.1007/s002280050477

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Single-dose pharmacokinetics of temocapr

Single-dose pharmacokinetics of temocapril and temocapril diacid in subjects with varying degrees of renal impairment

✍ B. Sierakowski; K. Püchler; P. U. Witte; K. Renneisen; I. Roots 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 186 KB

Single- and multiple-dose pharmacokineti

Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment

✍ S. Schumacher; I. Abbasi; D. Weise; V. Hatorp; K. Sattler; J. Sieber; C. Hasslac 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 112 KB

Single-dose pharmacokinetics of nefazodo

Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment

✍ R. H. Barbhaiya; D. S. Greene; U. A. Shukla 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 658 KB

The single-dose pharmacokinetics of nefazodone (NEF) and its metabolites hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were examined in 12 healthy younger subjects < 55 years of age (YNG), 12 elderly subjects > 65 years of age (ELD), 12 patients with biopsy proven hepatic cirrhosis

Depressor effects and pharmacokinetics o

Depressor effects and pharmacokinetics of single and consecutive doses of delapril in hypertensive patients with normal or impaired renal function

✍ Kohsuke Minamisawa; Hiroshi Shionoiri; Koh-ichi Sugimoto; Shin-ichiro Ueda; Kazu 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 539 KB

Pharmacokinetics and effects on blood pr

Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment

✍ R. Larsson; H. Liedholm; K. E. Andersson; M. A. Keane; G. Henry 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 528 KB

An open-label study to describe pharmaco

An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function

✍ Cindy L. O’Bryant; Paul Haluska; Lee Rosen; Ramesh K. Ramanathan; Balaji Venugop 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 364 KB